Enzyme PB digestive enzymes
Magnesium bisglycinate
Orange B vitamin complex
Driada Medical GLP-1

GLP-1 Safe Use Bundle

The three essentials your body needs during GLP-1 therapy: smoother digestion, steady energy, balanced mood.

  • Digestive Enzymes
  • Magnesium
  • B-Complex

GLP-1 receptor agonist therapy is inherently associated with delayed gastric emptying and altered intestinal motility. This reflects the core mechanism of action and primary physiological effects of GLP-1 receptor agonists.

However, gastrointestinal (GI) symptoms can still manifest even when:

  • The dose is titrated gradually, strictly adhering to recommended guidelines;
  • Dietary intake is split into small portions, accompanied by adequate hydration, while avoiding high-fat and high-carbohydrate foods.

These symptoms are not directly linked to impaired pancreatic enzyme secretion, as GLP-1 agonists do not cause an inherent deficiency. Interestingly, symptoms of bloating and postprandial fullness following the consumption of protein- and fiber-rich meals (which are essential to maintain lean muscle mass and maximize fat loss) are readily alleviated by digestive enzyme supplementation. This approach is supported by recent data from a notable retrospective study presented at the

19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2026)

"Incorporating PERT into treatment regimens may improve patient tolerance to GLP-1 receptor agonists, thereby enabling long-term compliance in the management of diabetes and obesity. The delayed gastric emptying and altered nutrient absorption observed with GLP-1 and dual GLP-1/GIP receptor agonist therapies may lead to a functional pancreatic insufficiency or a desynchronization between food transit and pancreatic secretion." https://www.medscape.com/viewarticle/pancreatic-enzyme-replacement-therapy-glp-1-symptoms-2026a10007zz?form

Consequently, pancreatic enzyme replacement therapy (PERT) is recommended and can significantly improve patient quality of life.

A reduced volume of food intake, combined with a baseline borderline deficiency status often found in individuals with obesity and metabolic disorders prior to therapy, underscores the clear necessity of incorporating essential baseline supplements, most notably magnesium and B-complex vitamins.

Magnesium serves as a crucial cofactor for over 300 enzymatic reactions in the body, ranging from protein synthesis and energy metabolism to neuromuscular conduction and blood pressure regulation. For individuals undergoing weight loss assisted by GLP-1 agonists, magnesium is critical across several pathways:

  • Electrolyte Balance:

Magnesium maintains the function of the Na+/K+-ATPase pump; its deficiency leads to intracellular potassium depletion and sodium accumulation. In the presence of diarrhea or inadequate fluid intake, the loss of magnesium and potassium is exacerbated, frequently causing muscle cramps and generalized fatigue.

  • Thyroid Function:

Magnesium acts as a key cofactor for enzymatic systems involved in the synthesis and metabolism of thyroid hormones. This is highly relevant for patients whose thyroid status may already be compromised due to a prolonged caloric deficit.

  • Insulin Sensitivity:

Magnesium deficiency is strongly associated with insulin resistance and metabolic syndrome—the very cluster of conditions for which GLP-1 agonist therapy is prescribed.

B6, B9, and B12 (The Methylation Cohort):

These three vitamins are well-known cofactors in the methylation cycle. In a restricted diet (particularly when animal protein intake decreases), methylation processes decline, leading to elevated homocysteine levels - a recognized independent cardiovascular risk factor.

Pyridoxal 5'-Phosphate (P5P):

As the active form of vitamin B6, P5P is a direct cofactor in the synthesis of dopamine and serotonin from tyrosine and tryptophan, respectively. On a calorie-restricted diet with reduced protein intake, this metabolic pathway is often the first to suffer, as the availability of precursor substrates (tyrosine/tryptophan) is already limited, and without sufficient P5P, their conversion into key neurotransmitters becomes severely impaired.